Chongqing Pharscin Pharmaceutical 华森制药
5 significant filings since 30 May 2026: 2 on acquisition or disposal, 1 on dividend and 1 on major holder selling, and 1 other kind. The latest, on 23 Sep 2026: 关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告.
自 30 May 2026 起有 5 份重大公告：acquisition or disposal 2 份、dividend 1 份、major holder selling 1 份，另有 1 类。最新一份（23 Sep 2026）：关于公司全资子公司受让成都华森奥睿药业有限公司股权的进展公告。
Price History 价格走势
1 session 个交易日, Thu 24 Sep 2026 · Live one-minute prices · High 最高 ¥14.81 · Low 最低 ¥14.41 · −1.90% on the previous close of ¥14.71The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 杜向阳 | Unrated | 25 Aug 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 1 report. 每行为该券商近十二个月的最新研报；1 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。